InsidersTradesSigma
Iovance Biotherapeutics, INC.: insider trades · United States · SEC (Form 4)
SEC:iovance-biotherapeutics-inc-9db83dUS·SEC (Form 4)
Discover the full insider trade history of Iovance Biotherapeutics, INC., a listed equity based in United States. Shares trade on US US, under the supervision of SEC (Form 4). The latest transaction was filed on 16 June 2022 (Levée d'options). Among the most active insiders: BILINSKY IGOR. All data is accessible without an account.
8
Insider Decl.
0
Thresholds
€3m
5 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
3.58 €
Analyst consensus
Valuation
P/Book2.2x
Beta0.69
Balance sheet & cash
Debt / Equity7%
Profitability & ownership
ROE-47.5%
ROA-23.6%
% insiders0.3%
% institutions67.4%
Last declaration on 16 June 2022
Declarations8 total
Executives◇Options12SEC
018,850 shares0
Common Stock
SEC:0001104659-22-071964:0·
Executives◇Options12SEC
019,690 shares0
Common Stock
SEC:0001104659-22-071967:0·
Executives◇Options20SEC
018,850 shares0
Common Stock
SEC:0001104659-22-071965:0·
Executives▲Purchase◆Signal · 45SEC
€13,8342,187 shares@ €6.3256100.0% of flow
Common Stock
SEC:0001104659-22-067761:0·
Ideal exit: 25 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 45SEC
€3m500,000 shares@ €6.3062100.0% of flow
Common Stock
SEC:0001104659-22-067757:0·
Ideal exit: 25 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 45SEC
€47,1287,500 shares@ €6.2837100.0% of flow
Common Stock
SEC:0001104659-22-067762:0·
Ideal exit: 25 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 45SEC
€63,72210,000 shares@ €6.3722100.0% of flow
Common Stock
SEC:0001104659-22-067763:0·
Ideal exit: 25 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 56SEC
€6,0451,000 shares@ €6.0446100.0% of flow
Common Stock
SEC:0001104659-22-067758:0·
Ideal exit: 26 Feb 2023 (T+270)
8 of 8 declarations